Australian survivors of the deadly meningococcal B strain are mounting pressure on the country's Pharmaceutical Benefits Advisory Committee to include Novartis' ($NVS) Bexsero, the only approved vaccine for the disease, on its national immunization plan when it meets next month. The committee has already rejected the jab once, dismissing the Swiss pharma's application last November on grounds that it wasn't worth the cost. But its counterpart in the U.K., for one, has already done an about-face on the vaccine: After leaving it off its national program, the country's Joint Committee on Vaccination and Immunisation in March OK'd Bexsero for all babies on the condition that Novartis negotiate a "cost-effective price." Story | More